Phase II trial of carboplatin in patients with advanced melanoma Academic Article Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Gene Expression Regulation, Developmental
  • Membrane Proteins
  • Neoplasm Proteins
  • Placenta
  • Trophoblasts

abstract

  • We report the results of a phase II evaluation of carboplatin (CBDCA) in 45 patients with advanced malignant melanoma. Of the 43 evaluable patients, 6 had been treated previously with chemotherapy; 11 had been treated with immunotherapy. The initial dose was 400 mg/m2 i.v. every 4 weeks; the dose was modified as required to achieve moderate myelosuppression. There was one complete response (duration 16 months) and six partial responses, for a major objective response rate of 16%. Toxicity consisted primarily of acute nausea and vomiting, and thrombocytopenia. The activity of CBDCA in this disease is similar to that of cisplatin and dacarbazine.

publication date

  • May 1990

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1007/BF00177256

PubMed ID

  • 1696568

Additional Document Info

start page

  • 187

end page

  • 90

volume

  • 8

number

  • 2